(Q113889149)

English

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation

clinical trial

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

instance of

clinical trial

0 references

title

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation (English)

0 references

0 references

0 references

United States of America

0 references

start time

20 May 2020

0 references

end time

31 May 2021

0 references

number of participants

60

0 references

research intervention

mavrilimumab

0 references

disease-modifying antirheumatic drug

0 references

clinical trial phase

phase II clinical trial

0 references

research subject recruitment status

unknown

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT04492514

0 references

(Q113889149)

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)